MS and Neurodegeneration: Brain Awareness Week

According to the MS International Federation, multiple sclerosis (MS) is one of the most common diseases of the central nervous system, and more than 2,300,000 people worldwide are living with the diagnosis of MS. MS is defined as an immune-mediated response, causing inflammatory demyelination (damage to the myelin sheath). It is this damage that is the cause of the various symptoms associated with MS (including blurred vision, weak limbs, tingling sensations, unsteadiness and fatigue).

However, research has provided increased knowledge about the disease and has made it apparent that MS has two major contributors, inflammation and neurodegeneration.

With the recognition of neurodegeneration as a contributing factor in MS, the evaluation of brain volume loss in a variety of brain regions is increasingly important. Not only for initial diagnosis, but also for assessing disease progression and the identifying different disease stages, as well as confirming the types of MS. Studying the impact of the affected brain structures and measuring the extent of the atrophy has brought more knowledge to the MS community. Researchers now recognize that atrophy occurs even in the early stages of MS, and not only as previously assumed at the late stages.

NeuroQuant® is a fully automatic, MRI post-processing solution that segments a large number of brain structures relevant to the assessment and ongoing monitoring of MS. It calculates the volumes and compares each volume to a normative database. This allows NeuroQuant to deliver a precise indication of where that individual’s brain structure volume lies within an age- and gender-based reference chart. The information provided by NeuroQuant allows a clinical user to take advantage of these research findings in evaluating their MS patients for the best possible care path.

  •  Raduea EW, Bendfeldta K, Mueller-Lenkea N, Magonc S, Sprengera T. Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis. Swiss Med Wkly. 2013;143:w13887
  • Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5(5):256–66
  • Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–31.

More Resources

11/10/2026

Cortechs.ai and Subtle Medical Partner to Deliver Faster MRI with Standardized Quantitative Neuroimaging

Cortechs.ai and Subtle Medical partner to accelerate MRI scans and deliver standardized, AI-powered quantitative neuroimaging.

10/30/2026

What to Expect at the Cortechs.ai Booth at RSNA 2026

Visit Cortechs.ai at RSNA 2026, Booth 5107. See Cortechs Connect, FDA-cleared NeuroQuant PET and live demos of our AI quantitative imaging tools.

10/14/2026

Cortechs.ai and CARPL.ai Partner to Expand Global Access to AI-Powered Imaging Solutions

Cortechs.ai joins CARPL.ai’s enterprise AI ecosystem to expand access to quantitative imaging solutions worldwide.

10/10/2026

World Mental Health Day: Why Brain Health and Mental Health Belong Together

Behind every brain scan is a person. Here’s why their voice matters.

09/30/2026

Today’s Examination Becomes Tomorrow’s Baseline: The Benefits of Performing Quantitative Analysis on Every Brain MRI

A single brain MRI shows where a patient is today. A quantitative baseline can help show how the brain changes over time.

09/18/2026

What a Head CT Can and Can’t Tell You About a Concussion

For Concussion Awareness Day, learn how quantitative CT analysis can help measure subtle structural changes and support follow-up after traumatic brain injury.
Scroll to Top